2024-514777-22-00已完成1 期
A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS120, which is an Antibody medication, to be administered alone or with Pembrolizumab in Subjects with Advanced Malignancies
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 113
- 试验地点
- 8
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
invoX Pharma Clinical Trials
Scientific
Invox Pharma Limited
研究点 (8)
Loading locations...
相似试验
招募中
1 期
A First-in-human Study to Evaluate the Safety and Anticancer Effect of Several Doses of TH9619 in Patients with Advanced Cancer (ODIN).2024-519639-40-00One-carbon Therapeutics AB33
招募中
1 期
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors2022-502867-39-00Amgen Inc.58
招募中
1 期
First-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTX-PID in healthy male volunteers2023-503892-83-00Vivet Therapeutics35
招募中
1 期
A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancers2025-522402-21-00Kupando GmbH21
招募中
1 期
A first-in-human trial to evaluate safety, tolerability, and pharmacokinetics of single and multiple oral doses of Debio 1453P in healthy adults2024-519328-26-01Debiopharm International S.A.88